Associated Papers
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.
Lang M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients.
Binhassan S et al.
Frontiers in Oncology, 2025
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H et al.
Anti-cancer Drugs, 2024
Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review.
Lazar R et al.
Frontiers in Oncology, 2024
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Chehrazi-Raffle A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.
Stensgaard S et al.
Translational Lung Cancer Research, 2023
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Rosai-Dorfman Disease between Proliferation and Neoplasia.
Elbaz Younes I et al.
Cancers, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis.
Chen J et al.
Leukemia, 2022
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F et al.
Cancer Treatment Reviews, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
Mayrhofer JE et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers.
Gopal P et al.
Nature Communications, 2019
Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V et al.
Current Problems in Cancer, 2019
Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G et al.
Human Pathology, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A et al.
Cancer Treatment Reviews, 2018
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Ashktorab H et al.
Oncotarget, 2017
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB et al.
Nature Communications, 2016
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.
Kim N et al.
Scientific Reports, 2016
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R et al.
Critical Reviews in Oncology/hematology, 2016
Integrated digital error suppression for improved detection of circulating tumor DNA.
Newman AM et al.
Nature Biotechnology, 2016
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.
Desai A et al.
Cancer Biology & Medicine, 2016
Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Peng S et al.
Oncotarget, 2016
Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.
Zhu L et al.
Plos One, 2016
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G et al.
Bmc Cancer, 2015
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Haley L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
Optimal drug prediction from personal genomics profiles.
Sheng J et al.
Ieee Journal of Biomedical and Health Informatics, 2015
Genomics driven-oncology: challenges and perspectives.
Normanno N et al.
Bmc Cancer, 2015
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.
Martelotto LG et al.
Genome Biology, 2014
Standardized decision support in next generation sequencing reports of somatic cancer variants.
Dienstmann R et al.
Molecular Oncology, 2014
Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
Meador CB et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
BRAF-mutations in non-small cell lung cancer.
Brustugun OT et al.
Lung Cancer (amsterdam, Netherlands), 2014
Recent advances in personalized lung cancer medicine.
Okimoto RA et al.
Personalized Medicine, 2014
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B et al.
Science Translational Medicine, 2012
Mutations of the p53 gene in gliomas from Malay patients.
Jafri A et al.
The Medical Journal of Malaysia, 2003